The study in Nature Medicine explores the potential wider benefits and risks of diabetes drugs GLP-1 receptor agonists.

A new study highlighted Monday the potential benefits of popular diabetes drugs on a wide range of health issues including ...

The medicines may not only suppress appetite but also help curb alcoholism and other addictions. Read more at straitstimes.com.

The market for GLP-1 drugs is projected to exceed $200 billion in annual sales by 2031, according to Morningstar Equity Research. Current market leaders include Novo Nordisk NVO and Eli Lilly LLY with ...

A new study highlighted Monday the potential benefits of popular diabetes drugs on a wide range of health issues including dementia and cardiovascular diseases, although experts warned against seeing ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

A study analyzing data from over 2 million veterans found that GLP-1 receptor agonists, popular weight-loss drugs like Ozempic and Wegovy, provide significant neurological and behavioral health ...

The study included nearly 2 million patients, making it the largest ever conducted on this group of glucagon-like peptide-1 ...

Insights from a study on GLP-1 receptor agonists reveal benefits for cardiometabolic health, with notable risks for ...

More than one-third of websites selling their own versions implied the products were the same as the FDA-approved drugs.

Over 2 million people were included in new research to test these drugs against 175 different health outcomes.

Weight-loss medicines such as Ozempic might raise a person’s likelihood of developing conditions including arthritis.